Table 4.
Temporal timing of antithrombotics and venous thromboembolic events by patient
| Patient | VTE | Timing of antithrombotic and venous thromboembolic events |
| Full | ||
| 3 | N/A | HD 1 PPX enox, HD1–5 FD hep (HD 6–10 ASA 325), HD 5–10 PPX enox, 10–12 and 14–16 FD hep (HD 12–14 FD enox), HD 16-20 FD apix; LOS 20 days |
| 5 | N/A | HD 2–4 PPX hep (HD 2–5 ASA), HD 4–6 FD hep, 7–9 FD enox, 10–16 FD dabigatran; LOS 16 days |
| 14 | N/A | HD 4–8 PPX hep, HD 12–19 FD hep; LOS 19 days |
| 18 | N/A | HD 3–4 PPX hep, HD 4–5 FD warfarin, HD 6–11 FD enox; LOS 11 days |
| Prophylactic with concomitant antiplatelet | ||
| 1 | N/A | HD 9–44 PPX hep (HD 15–35 ASA), HD 44–46 FD hep (our HD 9), HD 52–71 PPX enox (HD 55–71 ASA), HD 1 IVC-F; LOS 71 days |
| 6 | N/A | HD 3–20 PPX enox with ASA; LOS 20 days |
| 7 | N/A | HD 1–7 PPX enox with ASA; LOS 7 days |
| 10 | N/A | HD 4–26 PPX dalteparin (HD 4–26 ASA 325); LOS 26 days |
| 11 | N/A | HD 4–12 FD hep, HD 24–54 PPX dalteparin (HD18-54 ASA 325); LOS 54 days |
| 12 | N/A | HD 3–8 PPX dalteparin (HD 4–6 ASA suppository, HD 7–8 ASA 325); LOS 8 days |
| 16 | N/A | HD 3–18 PPX hep (HD 17–18 ASA 325); LOS 18 days |
| 21 | 4 PE | HD 2–4 PPX enox (HD 2–4 ASA suppository), HD 4–20 FD enox (HD 4–23 ASA 325), HD 20–23 FD apix; LOS 23 days |
| 22 | 11 DVT | HD 2–19 PPX hep (HD 3–25 ASA 81), HD 19–33 FD hep, HD 34–44 PPX hep, HD 44–46 PPX enox, HD 12 IVC-F; LOS 59 |
| 25 | 10 DVT | HD 3–7 PPX hep (HD 4–51 ASA 81), HD 8–11 PPX dalteparin, HD 11–51 FD dalteparin, HD 31–51 warfarin (took a while for INR to become therapeutic); LOS 51 days |
| Prophylactic anticoagulation | ||
| 2 | N/A | HD 2–48 PPX hep (HD 6–10 ASA), HD 48–58 PPX enox; LOS 58 days |
| 4 | N/A | HD 0–6 PPX enox; LOS 6 days |
| 8 | N/A | HD 3–9 PPX enox; LOS 9 days |
| 9 | N/A | HD 1–125 PPX hep (HD 3–22 ASA suppository); LOS 125 days |
| 19 | 5 DVT, 23 PE | HD 3–5 PPX enox, HD 5–11 PPX hep (HD 7–9 ASA suppository, HD 10–28 ASA 325), HD 12–28 PPX enox, HD 29 FD hep, HD 30–77 FD enox; LOS 77 |
| 20 | 5 DVT | HD 2–5 PPX hep, HD 5–9 FD hep, HD 9–10 PPX hep, HD 10 IVC-F; LOS 17 |
| 23 | 7 DVT, 8 PE | HD 3–4 PPX hep, HD 4–8 PPX enox, HD 8–9 FD hep, HD 9–34 FD enox, HD 32–34 warfarin, HD 9 IVC-F; LOS 34 days |
| 24 | 3 DVT | HD 2–3 PPX hep, HD 3–36 FD hep, HD 34–44 warfarin; LOS 44 days |
| No antithrombotics | ||
| 13 | N/A | No antithrombotics; LOS 3 |
| 15 | N/A | No antithrombotics; LOS 41 days |
| 17 | 1 DVT | HD 3–4 PPX hep, HD 4–24 FD hep, HD 24–30 FD enox, HD 30–37 FD hep, HD 38–54 FD enox, HD 54 dalteparin; LOS 54 days |
| 26 | 11 PE, 19 DVT | HD 3–8 PPX hep, HD 8–10 FD hep, HD 14–29 FD hep, HD 11 IVC-F; LOS 34 days |
apix, apixaban; ASA, aspirin; DVT, deep vein thrombosis; enox, enoxaparin; FD, full dose; HD, hospital day; hep, heparin; INR, international normalized ratio; IVC-F, inferior vena cava filter; LOS, length of stay; N/A, not applicable; PE, pulmonary embolism; PPX, prophylactic dose; VTE, venous thromboembolism.